Cytek Biosciences Inc — Quarterly Cash Flow (NASDAQ:CTKB) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 491.23 M499.5 M482.6 M493.32 M494.92 M461.54 M Total liabilities 105.76 M103.76 M102.97 M115.76 M116.35 M119.8 M Total equity 385.46 M395.74 M379.62 M377.56 M378.57 M341.74 M Total liabilities & shareholders' equities 491.23 M499.5 M482.6 M493.32 M494.92 M461.54 M Total debt —————— Net debt ——————

Noticias

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences earnings missed by $0.32, revenue topped estimates

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:CTKB) 2026-01-15

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth (CTKB)

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Beyond Meat (NASDAQ:BYND), Avadel Pharmaceuticals (NASDAQ:AVDL)

Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates

Cytek Biosciences kazancı $0,01 ile beklentilere göre daha kötü, kâr ise beklentilere göre yüksek

Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?

Cytek Biosciences: Growth Over Profit Will Pay Off In The Long Term (NASDAQ:CTKB)